▲ +85.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nephros in the last 3 months. The average price target is $14.25, with a high forecast of $16.00 and a low forecast of $12.50. The average price target represents a 85.06% upside from the last price of $7.70.
The current consensus among 2 investment analysts is to buy stock in Nephros. This rating has held steady since September 2019, when it changed from a Hold consensus rating.
Nephros, Inc., a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.